Masonic Cancer Center, University of Minnesota | Strategic Alliance Partners

The Masonic Cancer Center, University of Minnesota, is the Twin Cities’ only Comprehensive Cancer Center, designated ‘Outstanding’ by the National Cancer Institute. As Minnesota’s Cancer Center, we have served the entire state for more than 30 years. Our researchers, educators, and care providers work to discover the causes, prevention, detection, and treatment of cancer and cancer-related diseases as well as provide whole-of-life care and resources for survivorship. Learn more at cancer.umn.edu

Connect with us:

Latest from Masonic Cancer Center, University of Minnesota

Dr Miller on the Use of NK Cell Therapy in Hematologic Malignancies

August 16, 2024

Video

Jeffrey S. Miller, MD, discusses research with natural killer cell therapy in patients with hematologic malignancies and other cancers.

Dr Yee on Neoadjuvant Datopotamab Deruxtecan in High-Risk, Early-Stage Breast Cancer

August 13, 2024

Video

Douglas Yee, MD, discusses neoadjuvant datopotamab deruxtecan in early-stage breast cancer

Dr Eckfeldt on the Implications of Improved MRD Testing in AML

July 19, 2024

Video

Craig Eckfeldt, MD, PhD, discusses how improved minimal residual disease testing methods have impacted the acute myeloid leukemia treatment paradigm.

Dr Juckett on the Evolving Treatment Paradigm in Relapsed/Refractory AML

July 18, 2024

Video

Mark Juckett, MD, discusses ways the treatment paradigm has changed for patients with relapsed/refractory acute myeloid leukemia.

Dr Maakaron on Choosing Between Bispecific Antibodies and CAR T-Cell Therapy in DLBCL

June 27, 2024

Video

Joseph Maakaron, MD, discusses factors that influence his decision to use bispecific antibodies or CAR T-cell therapy in patients with DLBCL.

Dr Hu on Choosing Between Bispecific Antibodies vs CAR T-Cell Therapy in DLBCL

June 27, 2024

Video

Marie Hu, MD, discusses her decision-making process when considering bispecific antibodies vs CAR T-cell therapy in patients with DLBCL.

CAR T-Cell Therapy vs Bispecific Antibodies: Picking an Approach in R/R DLBCL

June 13, 2024

Article

Marie Hu, MD, discusses considerations for the use of CAR T-cell therapy and bispecific antibodies in relapsed/refractory diffuse large B-cell lymphoma.

Recent Data Shed Further Light on the MDS Treatment Paradigm as the SOC Evolves

May 30, 2024

Article

Jeremy Allred, MD, details current and emerging treatments for patients with myelodysplastic syndrome, highlighting recent key data updates.

Desai Details Efforts Exploring Treatment Strategies in CLL Post–BTK Inhibitor Progression

May 28, 2024

Article

Sanjal Desai, MD, discusses the feasibility of venetoclax rechallenge following progression on BTK inhibitors in chronic lymphocytic leukemia.

Genetic Information and Patient Factors Influence BTK Inhibitor Sequencing in Frontline CLL and Beyond

May 24, 2024

Article

Sanjal Desai, MD, expands on the safety, efficacy, and sequencing of BTK inhibitors and venetoclax-based regimens in chronic lymphocytic leukemia.

Eckfeldt Looks Towards the Future of AML and MDS Care

May 22, 2024

Article

Craig Eckfeldt, MD, PhD, discusses key updates in the MDS treatment paradigm and the implications of MRD testing, as well as next steps in the field of AML.

Prognostic Study Correlates TSP and Clinical Outcomes in High-Grade Serous Ovarian Cancer

May 17, 2024

Article

TSP is a reliable marker of clinical outcome measures, including platinum chemoresistance, PFS, and OS, in high-grade serous ovarian cancer.

Dr Lou on the Predictive and Prognostic Utility of Tumor Stroma Proportion in Ovarian Cancer

May 15, 2024

Video

Emil Lou, MD, PhD, FACP, discusses the predictive and prognostic value of tumor stroma proportion for survival outcomes in ovarian cancer.

Dr Antonarakis on Community Enrollment in the ECLIPSE Trial in Prostate Cancer

March 29, 2024

Video

Emmanuel Antonarakis, MD, discusses community enrollment in the ECLIPSE trial in prostate cancer.

Drs Jha and Antonarakis on Collaboration Between Community and Academic Oncologists

March 29, 2024

Video

Gautam Jha, MD, and Emmanuel Antonarakis, MD, on the advantages of collaborative efforts between community and academic oncologists.

Dr Antonarakis on Early Intervention With PARP Inhibitors in mHSPC

March 20, 2024

Video

Emmanuel Antonarakis, MD, discusses the significance of TALPRO-3, EVOPAR, and AMPLITUDE trials on the metastatic prostate cancer treatment paradigm.

Community/Academic Research Collaboration Paves the Way for Improved Cancer Care

March 11, 2024

Article

Gautam Jha, MD, and Emmanuel Antonarakis, MD, discuss the ins and outs of clinical trial partnerships between community and academic cancer centers.

Community-Based Clinical Trial Enrollment Expands Access to Prostate Cancer Care

March 06, 2024

Article

Gautam Jha, MD, and Emmanuel Antonarakis, MD, discuss enrollment to the ECLIPSE trial in community and academic cancer center settings.

Outreach and Engagement: Colleagues Come Together to Improve Community Care

January 29, 2024

Article

Kiara Ellis, MSW, details community outreach and engagement conversations centered around key matters affecting NCI-designated cancer centers.

Dr. Bachanova on NK Cell Therapy in NHL

March 22, 2023

Video

Veronika Bachanova, MD, PhD, discusses findings from a spatial analysis of the tumor microenvironment in patients with non-Hodgkin lymphoma who received and responded to adoptive natural killer cell therapy.